Synlogic (Nasdaq: SYBX) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Aug. 25, 2017 --

What: 
Synlogic (Nasdaq:SYBX), a pioneer in the development of Synthetic Biotic^TM medicines, a novel class of living medicines, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, JC Gutiérrez-Ramos, President & CEO, will ring the Closing Bell. 

Where:
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:
Monday, August 28, 2017 – 3:45 p.m. to 4:00 p.m. ET   

Synlogic Contact:
Elizabeth Wolffe, Ph.D.
510-710-8767
[email protected]

Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
[email protected]

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About Synlogic™
Synlogic™ is pioneering the development of a novel class of living treatments, Synthetic Biotic medicines, based on its proprietary drug discovery and development platform. Synlogic uses the tools and principles of synthetic biology to genetically reengineer beneficial, probiotic microbes that are designed to perform critical functions missing or damaged due to disease. Synlogic’s initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com  

-NDAQA-